BridgeBio LLC
NEWS
The first full business week of the new year began with plenty of clinical trial news. Here’s a look.
Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
Preclinical data shows SHP2 inhibitor enhances activity of osimertinib in EGFR-driven tumor xenografts
BridgeBio launched Charlotte, N.C.-based ML Bio Solutions to develop the LGMD2i asset BBP-418, a substrate supplementation therapy.
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
BridgeBio Pharma, Inc. has announced the pricing of its initial public offering of 20,500,000 shares of its common stock at a price to the public of $17.00 per share, as detailed in the company’s press release.
Two of this week’s biotech startup initial public offerings, BridgeBio and Adaptive Biotechnologies, have market values exceeding the magic $1 billion mark, and have recently launched initial public offerings (IPOs), but also increased their fundraising goals.
This week marked initial public offering news from six biopharma companies. Here’s a look.
JOBS
IN THE PRESS